The Trump administration Department of Justice says women and babies whose lives and safety are threatened by popular abortion pills should have to wait until after U.S. Food and Drug Administration’s review of the popular abortion drug mifepristone to get relief.

The DOJ is redirecting its demands for a court-mandated pause on abortion pill lawsuits from the landmark Louisiana v. FDA case to take aim at Texas and Florida for challenging the FDA’s 2000 approval of mifepristone and subsequent expansions. It is under the Biden administration’s 2023 radical mifepristone permissions that anyone in any state can order mail-order pregnancy-ending pills and complete at-home abortions without medical oversight.

In its memorandum filed on Friday, the DOJ demanded the court “stay this litigation pending the outcome of FDA’s review” or dismiss the complaint altogether.

“Florida and Texas (Plaintiffs) threaten to short-circuit the agency’s orderly review and study of the safety risks of mifepristone,” the memo claims. “They would have this Court set aside the 2000 approval of mifepristone and subsequent actions modifying the conditions of use (including the REMS) and approving generic equivalents — all without the benefit of FDA’s new review of the mifepristone REMS. And if FDA ultimately decides to change course, judicial relief may prove equally unnecessary and disruptive.” (REMS stands for Risk Evaluation and Mitigation Strategies.)

Both U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary pledged to review safety concerns surrounding the most popular abortion drug on the market, including one analysis that found more than one in 10 women who take mifepristone suffer a serious adverse event such as hemorrhage or infection. (Read more from “Trump DOJ Demands Pause On Another Lawsuit Challenging FDA’s Abortion Pill Permissions” HERE)